J Ophthalmic Inflamm Infect:体外超声碎石治疗免疫功能正常的女性肾结石患者后出现单侧内源性念珠菌性眼内炎

2019-04-30 不详 网络

伊朗设拉子医科大学Poostchi眼科研究中心的Shirvani M等人近日在J Ophthalmic Inflamm Infect杂志上发表了一篇文章,他们报告称,健康女性在进行体外超声碎石术(ESWL)后可能引起内源性念珠菌眼内炎,进而导致灾难性的视力威胁。

伊朗设拉子医科大学Poostchi眼科研究中心的Shirvani M等人近日在J Ophthalmic Inflamm Infect杂志上发表了一篇文章,他们报告称,健康女性在进行体外超声碎石术(ESWL)后可能引起内源性念珠菌眼内炎,进而导致灾难性的视力威胁。

这是一名32岁的女性患者,因眼睛视力模糊和右眼浮肿而到眼科诊所就医。她在就医前1周接受了ESWL肾结石治疗。眼底检查显示,其中央凹的白色病变显着升高,边缘蓬松。玻璃体取样的涂片诊断显示,存在假菌丝和芽殖酵母寄生。系统性、免疫性和传染性检查未发现异常。

对于该患者,作者进行玻璃体内和静脉注射两性霉素B和口服氟康唑治疗,治疗效果非常良好。在治疗六周后,浸润性病变完全消失。

因此,作者认为,肾结石碎石手术后引起的内源性念珠菌性眼内炎是一种严重且罕见的眼内感染,可能发生在没有任何危险因素的健康个体中。

原文出处:

Shirvani, M., et al., Unilateral endogenous Candida endophthalmitis after extracorporeal shock wave lithotripsy for a renal stone in an immunocompetent woman: a case report. J Ophthalmic Inflamm Infect, 2019. 9(1): p. 5.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693391, encodeId=d9441693391d8, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Tue Feb 11 17:41:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670602, encodeId=240116e060257, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun Dec 22 08:41:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682036, encodeId=aab216820364e, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Wed Feb 19 17:41:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057658, encodeId=2087205e65830, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Feb 15 12:41:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454857, encodeId=6015145485e50, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513538, encodeId=154015135386f, content=<a href='/topic/show?id=9293289e30d' target=_blank style='color:#2F92EE;'>#免疫功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28973, encryptionId=9293289e30d, topicName=免疫功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541444, encodeId=f9c81541444a9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693391, encodeId=d9441693391d8, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Tue Feb 11 17:41:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670602, encodeId=240116e060257, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun Dec 22 08:41:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682036, encodeId=aab216820364e, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Wed Feb 19 17:41:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057658, encodeId=2087205e65830, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Feb 15 12:41:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454857, encodeId=6015145485e50, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513538, encodeId=154015135386f, content=<a href='/topic/show?id=9293289e30d' target=_blank style='color:#2F92EE;'>#免疫功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28973, encryptionId=9293289e30d, topicName=免疫功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541444, encodeId=f9c81541444a9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693391, encodeId=d9441693391d8, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Tue Feb 11 17:41:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670602, encodeId=240116e060257, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun Dec 22 08:41:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682036, encodeId=aab216820364e, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Wed Feb 19 17:41:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057658, encodeId=2087205e65830, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Feb 15 12:41:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454857, encodeId=6015145485e50, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513538, encodeId=154015135386f, content=<a href='/topic/show?id=9293289e30d' target=_blank style='color:#2F92EE;'>#免疫功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28973, encryptionId=9293289e30d, topicName=免疫功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541444, encodeId=f9c81541444a9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693391, encodeId=d9441693391d8, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Tue Feb 11 17:41:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670602, encodeId=240116e060257, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun Dec 22 08:41:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682036, encodeId=aab216820364e, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Wed Feb 19 17:41:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057658, encodeId=2087205e65830, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Feb 15 12:41:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454857, encodeId=6015145485e50, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513538, encodeId=154015135386f, content=<a href='/topic/show?id=9293289e30d' target=_blank style='color:#2F92EE;'>#免疫功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28973, encryptionId=9293289e30d, topicName=免疫功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541444, encodeId=f9c81541444a9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=)]
    2020-02-15 柳叶一刀
  5. [GetPortalCommentsPageByObjectIdResponse(id=1693391, encodeId=d9441693391d8, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Tue Feb 11 17:41:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670602, encodeId=240116e060257, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun Dec 22 08:41:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682036, encodeId=aab216820364e, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Wed Feb 19 17:41:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057658, encodeId=2087205e65830, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Feb 15 12:41:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454857, encodeId=6015145485e50, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513538, encodeId=154015135386f, content=<a href='/topic/show?id=9293289e30d' target=_blank style='color:#2F92EE;'>#免疫功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28973, encryptionId=9293289e30d, topicName=免疫功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541444, encodeId=f9c81541444a9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=)]
    2019-05-02 xiaoyeshuang
  6. [GetPortalCommentsPageByObjectIdResponse(id=1693391, encodeId=d9441693391d8, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Tue Feb 11 17:41:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670602, encodeId=240116e060257, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun Dec 22 08:41:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682036, encodeId=aab216820364e, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Wed Feb 19 17:41:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057658, encodeId=2087205e65830, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Feb 15 12:41:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454857, encodeId=6015145485e50, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513538, encodeId=154015135386f, content=<a href='/topic/show?id=9293289e30d' target=_blank style='color:#2F92EE;'>#免疫功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28973, encryptionId=9293289e30d, topicName=免疫功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541444, encodeId=f9c81541444a9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1693391, encodeId=d9441693391d8, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Tue Feb 11 17:41:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670602, encodeId=240116e060257, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun Dec 22 08:41:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682036, encodeId=aab216820364e, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Wed Feb 19 17:41:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057658, encodeId=2087205e65830, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Feb 15 12:41:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454857, encodeId=6015145485e50, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513538, encodeId=154015135386f, content=<a href='/topic/show?id=9293289e30d' target=_blank style='color:#2F92EE;'>#免疫功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28973, encryptionId=9293289e30d, topicName=免疫功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541444, encodeId=f9c81541444a9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu May 02 10:41:00 CST 2019, time=2019-05-02, status=1, ipAttribution=)]